PADCEV: An Evolution in the Therapeutic Landscape of Urothelial Cancer

Time: 8:40 am
day: Day One

Details:

• Assessing ADCs as a new therapeutic class in bladder cancer and PADCEV’s unique mechanism of action
• Analyzing data on efficacy/safety of PADCEV in metastatic urothelial cancer and ongoing exploration of its activity in early bladder cancer
• Evaluating PADCEV as an MMAE-class ADC and its potential synergy with immunotherapy

Speakers: